G. Lopes
Sylvester Comprehensive Cancer Center · 53 works · 381 citations · h-index 10
Top works
- Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials
- Electronic nicotine delivery systems (ECs) and COVID-19: the perfect storm for young consumers
- Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC
- 1913O Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)
- Medical Oncology Workload in Canada: Infrastructure, Supports, and Delivery of Clinical Care
- FP13.04 KEYNOTE-042 3-Year Survival Update: 1L Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ Locally Advanced/Metastatic NSCLC
- P2.03-006 How Many Years of Life Have We Lost in Brazil Due to the Lack of Access to Anti-EGFR TKIs in the National Public Health System?
- P1.01-68 Correlation of the Lung Immune Prognostic Index (LIPI) and PDL1 Status with Outcomes for Immune Checkpoint Inhibitors in Advanced NSCLC Patients
- The use of biosimilar medicines in oncology - position statement of the Brazilian Society of Clinical Oncology (SBOC)
- LBA72 Assessment of clinical and laboratory prognostic factors in patients with cancer and SARS-CoV-2 infection: The COVID-19 and Cancer Consortium (CCC19)
- 3122 The role of PD-L1 expression as a predictive biomarker in advanced non-small cell lung cancer: A network meta-analysis
- Treatment with pralsetinib (formerly BLU-667), a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC)
- P1.11-001 Economic Impact of Immune Checkpoint Inhibitor Therapy in Brazil and Strategies to Improve Access
- Cost effectiveness and estimate of economical impact of immune checkpoint inhibitors for NSCLC relative to PD-L1 expression
- 1172MO Durvalumab consolidation in patients with stage III non-resecable NSCLC with driver genomic alterations
- Gemcitabine and oxaliplatin (GEMOX), a promissing combination for the treatment of relapsed, advanced or metastatic non small cell lung cancer (NSCLC)
- Overall Survival of Patients with Advanced NSCLC Treated with Nivolumab Correlates with Texture Features on Pre-Immunotherapy CT Imaging and Radiotherapy History
- MO01.38 Registrational Dataset from the Phase 1/2 ARROW Trial of Pralsetinib (BLU-667) in Patients with Advanced RET Fusion+ Non-Small-Cell Lung Cancer (NSCLC)
- P01.09 Improved Outcomes With Ramucirumab & Docetaxel in Metastatic Non-Small Cell Lung Cancer After Failure of Immunotherapy
- P1.04-19 Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios Predict Survival After Immunotherapy in Non-Small Cell Lung Cancer